Stemina Biomarker Discovery

Executive Summary

Stemina Biomarker Discovery is a biotechnology company leveraging human pluripotent stem cells and metabolomics to develop predictive toxicology assays and neurological diagnostics. Its platform identifies biomarkers of toxicity, offering a human-relevant alternative to animal testing for drug candidates, chemicals, and consumer products. The company operates two business units: Stemina, which provides toxicology testing services to pharmaceutical and chemical companies, and NeuroPointDX, which focuses on developing diagnostic tests for neurological disorders, including autism spectrum disorder (ASD). Stemina's approach addresses the growing regulatory and ethical push to reduce animal testing, while NeuroPointDX targets a large unmet need for objective biomarkers in neurodevelopmental conditions. The company has been active since 2007 and is headquartered in Madison, Wisconsin.

Upcoming Catalysts (preview)

• Q2 2027FDA clearance or CLIA validation of NeuroPointDX autism diagnostic test40% success
• Q4 2026Major partnership or licensing deal for toxicology services with a top-20 pharma company50% success
• Q2 2026Series C financing round to support commercialization of NeuroPointDX pipeline60% success